Ausgabe 2/2025
Inhalt (33 Artikel)
Standardization of the nomenclature of bone status indices: a milestone in diagnostic consistency and clarity
- Editorial
Etienne Cavalier, Richard Pikner, Samuel D. Vasikaran, Harjit Pal Bhattoa, Konstantinos Makris, Eugene V. McCloskey, Nicholas C. Harvey, Niklas Rye Jørgensen, Giovanni Lombardi
Rationale for osteoporosis screening in men
- Open Access
- Viewpoints
Radhika R. Narla, Robert A. Adler
Gut microbiome and bone health: update on mechanisms, clinical correlations, and possible treatment strategies
- Review
Andrea Ticinesi, Carmine Siniscalchi, Tiziana Meschi, Antonio Nouvenne
Effect of yoga on balance, falls, and bone metabolism: a systematic review of randomized controlled trials in healthy individuals
- Review
Paras Bajaj, Lakshmi Nagendra, Abha Bajaj, Miny Samuel, Manju Chandran
Impact of the guidance on fracture Liaison Services and the introduction of a new fee for secondary fracture prevention in Japan: Implementation of secondary fracture prevention during hospitalization for fragility fractures
- Open Access
- Original Article
Gaku Gondo, Jung-ho Shin, Susumu Kunisawa, Yuichi Imanaka
Bisphosphonate drug holidays in osteoporosis according to fracture risk profile
- Original Article
Asunción Salmoral, P. Peris, C. López Medina, H. Flórez, M. Barceló, M. Pascual Pastor, I. Ros, D. Grados, P. Aguado, S. García, L. López, L. Gifre, D. Cerdá, F. J. Aguilar, B. Panero, E. Costa, E. Casado, B. Hernández, A. Martínez Ferrer, J. Graña, I. Gómez, N. Guañabens
Association of standardized serum 25-hydroxyvitamin D with falls in post-menopausal women
- Original Article
Neil Binkley, Christopher T. Sempos, Gretta Borchardt, Jennifer Larsen, Mark L. Stacey, Samuel Mosiman, Joan M. Lappe
The effect of denosumab on minimum 3-years BMD changes in patients with osteoporotic hip fractures: a propensity score matching analysis
- Original Article
Chul-Ho Kim, Keunho Kim, Ji Wan Kim
Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage
- Original Article
Tej D. Azad, Rachel J. Wu, Kelly E. Anderson, Michael Darden, Amit Jain
Association of serum alkaline phosphatase levels with bone mineral density, osteoporosis prevalence, and mortality in US adults with osteoporosis: evidence from NHANES 2005–2018
- Original Article
Ran Chen, Kai Gong, Wei Chen, Zongfeng Chen, Xiang Hua, Jiaxin Tan, Yu Tian, Dong Liu, Lianyang Zhang, Ying Tang, Yang Li, Siru Zhou
The impact of a fracture liaison service with in-hospital anti-osteoporosis treatment on subsequent hip fracture and mortality rates—a single-center retrospective study
- Open Access
- Original Article
Uri Yoel, Hadar Alkobi Weiss, Adi Goldbart, Ethel Silverman Siris, David Louis Fisher, Lior Hassan, Merav Fraenkel
Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Indian women: a Markov microsimulation model analysis
- Original Article
Lakshmi Nagendra, Manju Chandran, Jean-Yves Reginster, Sanjay Kumar Bhadada, Saptarshi Bhattacharya, Deep Dutta, Mickael Hiligsmann
Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass
- Original Article
Seunghyun Lee, Namki Hong, Sung Joon Cho, Sungjae Shin, Yumie Rhee
Bilateral femoral neck fractures in pregnancy suggestive of transient osteoporosis of the hip in a patient with hyperparathyroidism: a case report
- Case Report
Ryan J. Blake, Vincent K. Melemai, Brody M. Fitzpatrick, David F. Hubbard, Matthew J. Dietz, Colleen M. Watkins
Comment on: Low-dose glucocorticoid increase the risk of fracture in postmenopausal women with low bone mass: a retrospective cohort study
- Letter to the Editor
Dongdong Cao, Neimeng Gu, Aifeng Liu
Letter to the Editor Regarding “The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland”
- Letter to the Editor
Jialin Yang, Dongdong Cao, Aifeng Liu
Response to the Letter to the Editor regarding “The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland” by Yang and colleagues
- Letter to the Editor
Judith Everts-Graber, Stephan Reichenbach, Thomas Lehmann
Bone density and microarchitecture in Graves’ disease: evaluating treatment and vitamin D supplementation
- Letter to the Editor
Wei-Zhen Tang, Zhi-Jian Zhou, Tai-Hang Liu
Bone density and microarchitecture in Graves’ disease: evaluating treatment and vitamin D supplementation
- Letter to the Editor
Diana Grove-Laugesen, Eva Ebbehoj, Torquil Watt, Klavs Würgler Hansen, Lars Rejnmark
Assessing the impact of the 5 Nations Consensus Paper on IV Zolendronate administration post-hip fracture in older patients: experience from a UK teaching hospital
- Letter to the Editor
J. Soopramanien, A. Wakefield, L. Marshall, J. Nightingale, O. Sahota
Artificial intelligence insights into osteoporosis: comment
- Letter to the Editor
Hinpetch Daungsupawong, Viroj Wiwanitkit
Author response to: OSIN-D-24–00381, artificial intelligence insights into osteoporosis
- Letter to the Editor
Yakup Erden, Mustafa Hüseyin Temel, Fatih Bağcıer
Comment on “Higher prevalence of thyroid‑specific autoantibodies (TPOAb and TgAb) is related to a higher prevalence of fractures in females: results from NHANES 2007–2010”
- Letter to the Editor
Ping Xu, Jianyang Luo
Author Response to: Comment from Cheng Gu and Yu Cui on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan
- Letter to the Editor
Masayuki Iki, Kenji Fujimori, Nobukazu Okimoto, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Hironori Imano, Sumito Ogawa
Comment on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan
- Letter to the Editor
Dongdong Cao, Zhiyang Cao, Aifeng Liu
Author response to: Comment from Dongdong Cao, et al. on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan
- Letter to the Editor
Masayuki Iki, Kenji Fujimori, Nobukazu Okimoto, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Hironori Imano, Sumito Ogawa
Optimizing patient outcomes post-glucocorticoid therapy: a call for enhanced monitoring and preventive care
- Letter to the Editor
Zahra Ali Haque, Rayyan Nabi, Hanzala Ahmed Farooqi
Author Response to: Comment from Zahra Ali Haque, et al. on: Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan
- Letter to the Editor
Masayuki Iki, Kenji Fujimori, Nobukazu Okimoto, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Hironori Imano, Sumito Ogawa
Proactive strategies for fracture risk in androgen deprivation therapy: a call for multidisciplinary collaboration
- Letter to the Editor
Muhammad Hunain Raza, Muhammad Eeman Bhutta, Muhammad Hammad Siddique
Author response to 01530, Proactive strategies for fracture risk in androgen deprivation therapy: a call for multidisciplinary collaboration
- Letter to the Editor
Marsha van Oostwaard, J. P. van den Bergh, C. E. Wyers
Comment on “Association of proton-density fat fraction with osteoporosis: a systematic review and meta-analysis”
- Letter to the Editor
Manoj Soni, Muhammed Shabil, Sanjit Sah
